MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
MII IG Kerndatensatz-Modul Onkologie
2027.0.0-ballot.1 -
Germany
This page is part of the MII IG Kerndatensatz-Modul Onkologie (v2027.0.0-ballot.1: Release) based on FHIR (HL7® FHIR® Standard) R4. This is the current published version in its permanent home (it will always be available at this URL). For a full list of available versions, see the Directory of published versions
| Active as of 2024-12-12 |
<ConceptMap xmlns="http://hl7.org/fhir">
<id value="mii-cm-onko-atc-transitions-2021"/>
<meta>
<extension
url="http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-license">
<valueCode value="CC-BY-4.0"/>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/package-source">
<extension url="packageId">
<valueId
value="de.medizininformatikinitiative.kerndatensatz.onkologie"/>
</extension>
<extension url="version">
<valueString value="2027.0.0-ballot.1"/>
</extension>
<extension url="uri">
<valueUri
value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko"/>
</extension>
</extension>
<profile
value="http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-shareableconceptmap"/>
<profile
value="http://hl7.org/fhir/uv/crmi/StructureDefinition/crmi-publishableconceptmap"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xml:lang="en" lang="en"><hr/><p><b>English</b></p><hr/><p class="res-header-id"><b>Generated Narrative: ConceptMap mii-cm-onko-atc-transitions-2021</b></p><a name="mii-cm-onko-atc-transitions-2021"> </a><a name="hcmii-cm-onko-atc-transitions-2021"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px"/><p style="margin-bottom: 0px">Profiles: <a href="http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-shareableconceptmap.html">CRMI Shareable ConceptMap</a>, <a href="http://hl7.org/fhir/uv/crmi/STU2/StructureDefinition-crmi-publishableconceptmap.html">CRMI Publishable ConceptMap</a></p></div><p>Mapping from <a href="ValueSet-mii-vs-onko-systemische-therapie-substanzen-2020.html">MII VS Onkologie Systemische Therapie Substanzen ATC 2020</a> to <a href="ValueSet-mii-vs-onko-systemische-therapie-substanzen-2021.html">MII VS Onkologie Systemische Therapie Substanzen ATC 2021</a></p><br/><p>Mapping from <code>http://fhir.de/CodeSystem/bfarm/atc</code> (Atc) to <code>http://fhir.de/CodeSystem/bfarm/atc</code> (Atc)</p><table class="grid"><tr><td><b>Source Code</b></td><td><b>Relationship</b></td><td><b>Target Code</b></td><td><b>Comment</b></td></tr><tr><td>L01XE01 (Imatinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EA01 (Imatinib)</td><td>Reklassifizierung zu BCR-ABL Tyrosinkinase-Inhibitoren</td></tr><tr><td>L01XE06 (Dasatinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EA02 (Dasatinib)</td><td/></tr><tr><td>L01XE08 (Nilotinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EA03 (Nilotinib)</td><td/></tr><tr><td>L01XE14 (Bosutinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EA04 (Bosutinib)</td><td/></tr><tr><td>L01XE24 (Ponatinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EA05 (Ponatinib)</td><td/></tr><tr><td>L01XE02 (Gefitinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EB01 (Gefitinib)</td><td>Reklassifizierung zu EGFR Tyrosinkinase-Inhibitoren</td></tr><tr><td>L01XE03 (Erlotinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EB02 (Erlotinib)</td><td/></tr><tr><td>L01XE13 (Afatinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EB03 (Afatinib)</td><td/></tr><tr><td>L01XE35 (Osimertinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EB04 (Osimertinib)</td><td/></tr><tr><td>L01XE15 (Vemurafenib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EC01 (Vemurafenib)</td><td>Reklassifizierung zu BRAF-Inhibitoren</td></tr><tr><td>L01XE23 (Dabrafenib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EC02 (Dabrafenib)</td><td/></tr><tr><td>L01XE46 (Encorafenib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EC03 (Encorafenib)</td><td/></tr><tr><td>L01XE16 (Crizotinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01ED01 (Crizotinib)</td><td>Reklassifizierung zu ALK-Inhibitoren</td></tr><tr><td>L01XE28 (Ceritinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01ED02 (Ceritinib)</td><td/></tr><tr><td>L01XE36 (Alectinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01ED03 (Alectinib)</td><td/></tr><tr><td>L01XE43 (Brigatinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01ED04 (Brigatinib)</td><td/></tr><tr><td>L01XE44 (Lorlatinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01ED05 (Lorlatinib)</td><td/></tr><tr><td>L01XE25 (Trametinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EE01 (Trametinib)</td><td>Reklassifizierung zu MEK-Inhibitoren</td></tr><tr><td>L01XE38 (Cobimetinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EE02 (Cobimetinib)</td><td/></tr><tr><td>L01XE41 (Binimetinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EE03 (Binimetinib)</td><td/></tr><tr><td>L01XE33 (Palbociclib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EF01 (Palbociclib)</td><td>Reklassifizierung zu CDK4/6-Inhibitoren</td></tr><tr><td>L01XE42 (Ribociclib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EF02 (Ribociclib)</td><td/></tr><tr><td>L01XE50 (Abemaciclib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EF03 (Abemaciclib)</td><td/></tr><tr><td>L01XE09 (Temsirolimus)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EG01 (Temsirolimus)</td><td>Reklassifizierung zu mTOR-Inhibitoren</td></tr><tr><td>L01XE10 (Everolimus)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EG02 (Everolimus)</td><td/></tr><tr><td>L01XE07 (Lapatinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EH01 (Lapatinib)</td><td>Reklassifizierung zu HER2-Inhibitoren</td></tr><tr><td>L01XE45 (Neratinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EH02 (Neratinib)</td><td/></tr><tr><td>L01XE18 (Ruxolitinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EJ01 (Ruxolitinib)</td><td>Reklassifizierung zu JAK-Inhibitoren</td></tr><tr><td>L01XE17 (Axitinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EK01 (Axitinib)</td><td>Reklassifizierung zu VEGFR-Inhibitoren</td></tr><tr><td>L01XE34 (Tivozanib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EK03 (Tivozanib)</td><td/></tr><tr><td>L01XE27 (Ibrutinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EL01 (Ibrutinib)</td><td>Reklassifizierung zu BTK-Inhibitoren</td></tr><tr><td>L01XE51 (Acalabrutinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EL02 (Acalabrutinib)</td><td/></tr><tr><td>L01XX47 (Idelalisib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EM01 (Idelalisib)</td><td>Reklassifizierung zu PI3K-Inhibitoren</td></tr><tr><td>L01XX61 (Copanlisib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EM02 (Copanlisib)</td><td/></tr><tr><td>L01XE04 (Sunitinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EX01 (Sunitinib)</td><td>Reklassifizierung zu andere Proteinkinase-Inhibitoren</td></tr><tr><td>L01XE05 (Sorafenib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EX02 (Sorafenib)</td><td/></tr><tr><td>L01XE12 (Vandetanib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EX04 (Vandetanib)</td><td/></tr><tr><td>L01XE21 (Regorafenib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EX05 (Regorafenib)</td><td/></tr><tr><td>L01XE26 (Cabozantinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EX07 (Cabozantinib)</td><td/></tr><tr><td>L01XE29 (Lenvatinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EX08 (Lenvatinib)</td><td/></tr><tr><td>L01XE31 (Nintedanib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EX09 (Nintedanib)</td><td/></tr><tr><td>L01XE39 (Midostaurin)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EX10 (Midostaurin)</td><td/></tr><tr><td>L01XE52 (Quizartinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EX11 (Quizartinib)</td><td/></tr><tr><td>L01XE53 (Larotrectinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EX12 (Larotrectinib)</td><td/></tr><tr><td>L01XE54 (Gilteritinib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01EX13 (Gilteritinib)</td><td/></tr><tr><td>L01XX14 (Tretinoin)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XF01 (Tretinoin)</td><td>Reklassifizierung zu Retinoide</td></tr><tr><td>L01XX22 (Alitretinoin)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XF02 (Alitretinoin)</td><td/></tr><tr><td>L01XX25 (Bexaroten)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XF03 (Bexaroten)</td><td/></tr><tr><td>L01XX32 (Bortezomib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XG01 (Bortezomib)</td><td>Reklassifizierung zu Proteasom-Inhibitoren</td></tr><tr><td>L01XX45 (Carfilzomib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XG02 (Carfilzomib)</td><td/></tr><tr><td>L01XX50 (Ixazomib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XG03 (Ixazomib)</td><td/></tr><tr><td>L01XX38 (Vorinostat)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XH01 (Vorinostat)</td><td>Reklassifizierung zu Histon-Deacetylase-Inhibitoren</td></tr><tr><td>L01XX39 (Romidepsin)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XH02 (Romidepsin)</td><td/></tr><tr><td>L01XX42 (Panobinostat)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XH03 (Panobinostat)</td><td/></tr><tr><td>L01XX49 (Belinostat)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XH04 (Belinostat)</td><td/></tr><tr><td>L01XX43 (Vismodegib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XJ01 (Vismodegib)</td><td>Reklassifizierung zu Hedgehog-Signalweg-Inhibitoren</td></tr><tr><td>L01XX63 (Glasdegib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XJ03 (Glasdegib)</td><td/></tr><tr><td>L01XX46 (Olaparib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XK01 (Olaparib)</td><td>Reklassifizierung zu PARP-Inhibitoren</td></tr><tr><td>L01XX54 (Niraparib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XK02 (Niraparib)</td><td/></tr><tr><td>L01XX60 (Talazoparib)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01XK04 (Talazoparib)</td><td/></tr><tr><td>L01XX17 (Topotecan)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01CE01 (Topotecan)</td><td>Reklassifizierung zu Topoisomerase-I-Inhibitoren</td></tr><tr><td>L01XX19 (Irinotecan)</td><td><a href="http://hl7.org/fhir/R4/codesystem-concept-map-equivalence.html#concept-map-equivalence-equivalent" title="equivalent">is equivalent to</a></td><td>L01CE02 (Irinotecan)</td><td/></tr></table></div>
</text>
<extension
url="http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability">
<valueCode value="shareable"/>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/cqf-knowledgeCapability">
<valueCode value="publishable"/>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-versionPolicy">
<valueCodeableConcept>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/artifact-version-policy-codes"/>
<code value="package"/>
<display value="Package"/>
</coding>
</valueCodeableConcept>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/resource-approvalDate">
<valueDate value="2026-09-15"/>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-topic">
<valueCodeableConcept>
<coding>
<system value="http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl"/>
<code value="C3262"/>
</coding>
</valueCodeableConcept>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
<valueContactDetail>
<telecom>
<system value="email"/>
<value value="thomas.debertshaeuser@charite.de"/>
</telecom>
</valueContactDetail>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-editor">
<valueContactDetail>
<name value="Taskforce Core Data Set"/>
</valueContactDetail>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-reviewer">
<valueContactDetail>
<name value="Interoperability Working Group"/>
<telecom>
<system value="url"/>
<value
value="https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"/>
</telecom>
</valueContactDetail>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-reviewer">
<valueContactDetail>
<name value="National Steering Committee"/>
<telecom>
<system value="url"/>
<value
value="https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"/>
</telecom>
</valueContactDetail>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-endorser">
<valueContactDetail>
<name value="Interoperability Working Group"/>
<telecom>
<system value="url"/>
<value
value="https://www.medizininformatik-initiative.de/en/collaboration/interoperability-working-group"/>
</telecom>
</valueContactDetail>
</extension>
<extension url="http://hl7.org/fhir/StructureDefinition/artifact-endorser">
<valueContactDetail>
<name value="National Steering Committee"/>
<telecom>
<system value="url"/>
<value
value="https://www.medizininformatik-initiative.de/en/collaboration/national-steering-committee"/>
</telecom>
</valueContactDetail>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/artifact-versionAlgorithm">
<valueCoding>
<system value="http://hl7.org/fhir/version-algorithm"/>
<code value="semver"/>
<display value="SemVer"/>
</valueCoding>
</extension>
<extension
url="http://hl7.org/fhir/StructureDefinition/resource-effectivePeriod">
<valuePeriod>
<start value="2027"/>
</valuePeriod>
</extension>
<url
value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ConceptMap/mii-cm-onko-atc-transitions-2021"/>
<version value="2027.0.0-ballot.1"/>
<name value="MII_CM_Onko_ATC_Transitions_2021"/>
<title value="MII CM Onko ATC Code Changes 2020 to 2021"/>
<status value="active"/>
<experimental value="false"/>
<date value="2024-12-12"/>
<publisher value="Medizininformatik Initiative"/>
<contact>
<name value="Medizininformatik Initiative"/>
<telecom>
<system value="url"/>
<value value="https://www.medizininformatik-initiative.de/"/>
</telecom>
</contact>
<description
value="Diese ConceptMap dokumentiert ausschließlich die ATC-Code-Änderungen von 2020 zu 2021. Im Jahr 2021 erfolgte eine umfassende Reorganisation der ATC-Klassifikation für onkologische Substanzen mit Umkodierung von über 60 Wirkstoffen."/>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="DE"/>
<display value="Germany"/>
</coding>
</jurisdiction>
<purpose
value="Migration von ATC-Codes für Substanzen, die 2021 umkodiert wurden. Enthält nur geänderte Codes, keine neuen oder unveränderten Einträge."/>
<sourceCanonical
value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2020"/>
<targetCanonical
value="https://www.medizininformatik-initiative.de/fhir/ext/modul-onko/ValueSet/mii-vs-onko-systemische-therapie-substanzen-2021"/>
<group>
<source value="http://fhir.de/CodeSystem/bfarm/atc"/>
<target value="http://fhir.de/CodeSystem/bfarm/atc"/>
<element>
<code value="L01XE01"/>
<display value="Imatinib"/>
<target>
<code value="L01EA01"/>
<display value="Imatinib"/>
<equivalence value="equivalent"/>
<comment
value="Reklassifizierung zu BCR-ABL Tyrosinkinase-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XE06"/>
<display value="Dasatinib"/>
<target>
<code value="L01EA02"/>
<display value="Dasatinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE08"/>
<display value="Nilotinib"/>
<target>
<code value="L01EA03"/>
<display value="Nilotinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE14"/>
<display value="Bosutinib"/>
<target>
<code value="L01EA04"/>
<display value="Bosutinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE24"/>
<display value="Ponatinib"/>
<target>
<code value="L01EA05"/>
<display value="Ponatinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE02"/>
<display value="Gefitinib"/>
<target>
<code value="L01EB01"/>
<display value="Gefitinib"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu EGFR Tyrosinkinase-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XE03"/>
<display value="Erlotinib"/>
<target>
<code value="L01EB02"/>
<display value="Erlotinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE13"/>
<display value="Afatinib"/>
<target>
<code value="L01EB03"/>
<display value="Afatinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE35"/>
<display value="Osimertinib"/>
<target>
<code value="L01EB04"/>
<display value="Osimertinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE15"/>
<display value="Vemurafenib"/>
<target>
<code value="L01EC01"/>
<display value="Vemurafenib"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu BRAF-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XE23"/>
<display value="Dabrafenib"/>
<target>
<code value="L01EC02"/>
<display value="Dabrafenib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE46"/>
<display value="Encorafenib"/>
<target>
<code value="L01EC03"/>
<display value="Encorafenib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE16"/>
<display value="Crizotinib"/>
<target>
<code value="L01ED01"/>
<display value="Crizotinib"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu ALK-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XE28"/>
<display value="Ceritinib"/>
<target>
<code value="L01ED02"/>
<display value="Ceritinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE36"/>
<display value="Alectinib"/>
<target>
<code value="L01ED03"/>
<display value="Alectinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE43"/>
<display value="Brigatinib"/>
<target>
<code value="L01ED04"/>
<display value="Brigatinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE44"/>
<display value="Lorlatinib"/>
<target>
<code value="L01ED05"/>
<display value="Lorlatinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE25"/>
<display value="Trametinib"/>
<target>
<code value="L01EE01"/>
<display value="Trametinib"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu MEK-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XE38"/>
<display value="Cobimetinib"/>
<target>
<code value="L01EE02"/>
<display value="Cobimetinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE41"/>
<display value="Binimetinib"/>
<target>
<code value="L01EE03"/>
<display value="Binimetinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE33"/>
<display value="Palbociclib"/>
<target>
<code value="L01EF01"/>
<display value="Palbociclib"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu CDK4/6-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XE42"/>
<display value="Ribociclib"/>
<target>
<code value="L01EF02"/>
<display value="Ribociclib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE50"/>
<display value="Abemaciclib"/>
<target>
<code value="L01EF03"/>
<display value="Abemaciclib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE09"/>
<display value="Temsirolimus"/>
<target>
<code value="L01EG01"/>
<display value="Temsirolimus"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu mTOR-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XE10"/>
<display value="Everolimus"/>
<target>
<code value="L01EG02"/>
<display value="Everolimus"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE07"/>
<display value="Lapatinib"/>
<target>
<code value="L01EH01"/>
<display value="Lapatinib"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu HER2-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XE45"/>
<display value="Neratinib"/>
<target>
<code value="L01EH02"/>
<display value="Neratinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE18"/>
<display value="Ruxolitinib"/>
<target>
<code value="L01EJ01"/>
<display value="Ruxolitinib"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu JAK-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XE17"/>
<display value="Axitinib"/>
<target>
<code value="L01EK01"/>
<display value="Axitinib"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu VEGFR-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XE34"/>
<display value="Tivozanib"/>
<target>
<code value="L01EK03"/>
<display value="Tivozanib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE27"/>
<display value="Ibrutinib"/>
<target>
<code value="L01EL01"/>
<display value="Ibrutinib"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu BTK-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XE51"/>
<display value="Acalabrutinib"/>
<target>
<code value="L01EL02"/>
<display value="Acalabrutinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XX47"/>
<display value="Idelalisib"/>
<target>
<code value="L01EM01"/>
<display value="Idelalisib"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu PI3K-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XX61"/>
<display value="Copanlisib"/>
<target>
<code value="L01EM02"/>
<display value="Copanlisib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE04"/>
<display value="Sunitinib"/>
<target>
<code value="L01EX01"/>
<display value="Sunitinib"/>
<equivalence value="equivalent"/>
<comment
value="Reklassifizierung zu andere Proteinkinase-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XE05"/>
<display value="Sorafenib"/>
<target>
<code value="L01EX02"/>
<display value="Sorafenib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE12"/>
<display value="Vandetanib"/>
<target>
<code value="L01EX04"/>
<display value="Vandetanib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE21"/>
<display value="Regorafenib"/>
<target>
<code value="L01EX05"/>
<display value="Regorafenib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE26"/>
<display value="Cabozantinib"/>
<target>
<code value="L01EX07"/>
<display value="Cabozantinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE29"/>
<display value="Lenvatinib"/>
<target>
<code value="L01EX08"/>
<display value="Lenvatinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE31"/>
<display value="Nintedanib"/>
<target>
<code value="L01EX09"/>
<display value="Nintedanib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE39"/>
<display value="Midostaurin"/>
<target>
<code value="L01EX10"/>
<display value="Midostaurin"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE52"/>
<display value="Quizartinib"/>
<target>
<code value="L01EX11"/>
<display value="Quizartinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE53"/>
<display value="Larotrectinib"/>
<target>
<code value="L01EX12"/>
<display value="Larotrectinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XE54"/>
<display value="Gilteritinib"/>
<target>
<code value="L01EX13"/>
<display value="Gilteritinib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XX14"/>
<display value="Tretinoin"/>
<target>
<code value="L01XF01"/>
<display value="Tretinoin"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu Retinoide"/>
</target>
</element>
<element>
<code value="L01XX22"/>
<display value="Alitretinoin"/>
<target>
<code value="L01XF02"/>
<display value="Alitretinoin"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XX25"/>
<display value="Bexaroten"/>
<target>
<code value="L01XF03"/>
<display value="Bexaroten"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XX32"/>
<display value="Bortezomib"/>
<target>
<code value="L01XG01"/>
<display value="Bortezomib"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu Proteasom-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XX45"/>
<display value="Carfilzomib"/>
<target>
<code value="L01XG02"/>
<display value="Carfilzomib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XX50"/>
<display value="Ixazomib"/>
<target>
<code value="L01XG03"/>
<display value="Ixazomib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XX38"/>
<display value="Vorinostat"/>
<target>
<code value="L01XH01"/>
<display value="Vorinostat"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu Histon-Deacetylase-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XX39"/>
<display value="Romidepsin"/>
<target>
<code value="L01XH02"/>
<display value="Romidepsin"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XX42"/>
<display value="Panobinostat"/>
<target>
<code value="L01XH03"/>
<display value="Panobinostat"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XX49"/>
<display value="Belinostat"/>
<target>
<code value="L01XH04"/>
<display value="Belinostat"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XX43"/>
<display value="Vismodegib"/>
<target>
<code value="L01XJ01"/>
<display value="Vismodegib"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu Hedgehog-Signalweg-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XX63"/>
<display value="Glasdegib"/>
<target>
<code value="L01XJ03"/>
<display value="Glasdegib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XX46"/>
<display value="Olaparib"/>
<target>
<code value="L01XK01"/>
<display value="Olaparib"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu PARP-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XX54"/>
<display value="Niraparib"/>
<target>
<code value="L01XK02"/>
<display value="Niraparib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XX60"/>
<display value="Talazoparib"/>
<target>
<code value="L01XK04"/>
<display value="Talazoparib"/>
<equivalence value="equivalent"/>
</target>
</element>
<element>
<code value="L01XX17"/>
<display value="Topotecan"/>
<target>
<code value="L01CE01"/>
<display value="Topotecan"/>
<equivalence value="equivalent"/>
<comment value="Reklassifizierung zu Topoisomerase-I-Inhibitoren"/>
</target>
</element>
<element>
<code value="L01XX19"/>
<display value="Irinotecan"/>
<target>
<code value="L01CE02"/>
<display value="Irinotecan"/>
<equivalence value="equivalent"/>
</target>
</element>
</group>
</ConceptMap>